ERBB2 and neoplasm: As shown in Fig. 1, more than 70.0% of respondents indicate tumor stage pT4, nodal positivity pN2-pN3, HER2 positivity and triple negativity (i.e. the absence of estrogen, progesteron receptor and HER2 amplification) as the most important factors to classify patients at high risk of disease progression.